Overview of Antagonists Used for Determining the Mechanisms of Action Employed by Potential Vasodilators with Their Suggested Signaling Pathways
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells
Int. J. Mol. Sci. 2015, 16, 5572-5589; doi:10.3390/ijms16035572 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Regulatory Effects of Caffeic Acid Phenethyl Ester on Neuroinflammation in Microglial Cells Cheng-Fang Tsai 1,†, Yueh-Hsiung Kuo 1,2,†, Wei-Lan Yeh 3, Caren Yu-Ju Wu 4, Hsiao-Yun Lin 5, 4 4 4 1 5,6, Sheng-Wei Lai , Yu-Shu Liu , Ling-Hsuan Wu , Jheng-Kun Lu and Dah-Yuu Lu * 1 Department of Biotechnology, Asia University, Taichung 413, Taiwan; E-Mails: [email protected] (C.-F.T.); [email protected] (Y.-H.K.); [email protected] (J.-K.L.) 2 Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung 404, Taiwan 3 Department of Cell and Tissue Engineering, Changhua Christian Hospital, Changhua 500, Taiwan; E-Mail: [email protected] 4 Graduate Institute of Basic Medical Science, College of Medicine, China Medical University, Taichung 404, Taiwan; E-Mails: [email protected] (C.Y.-J.W.); [email protected] (S.-W.L.); [email protected] (Y.-S.L.); [email protected] (L.-H.W.) 5 Graduate Institute of Neural and Cognitive Sciences, China Medical University, Taichung 404, Taiwan; E-Mail: [email protected] 6 Department of Photonics and Communication Engineering, Asia University, Taichung 413, Taiwan † These authors contributed equally to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +886-4-2205-3366 (ext. 8206); Fax: +886-4-2207-1507. Academic Editor: Guido R. -
Rhynchophylline Loaded-Mpeg-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimer's Disease
International Journal of Nanomedicine Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Rhynchophylline Loaded-mPEG-PLGA Nanoparticles Coated with Tween-80 for Preliminary Study in Alzheimer’sDisease This article was published in the following Dove Press journal: International Journal of Nanomedicine Ruiling Xu1 Purpose: Alzheimer’s disease (AD) is a growing concern in the modern society. The current Junying Wang1 drugs approved by FDA are not very promising. Rhynchophylline (RIN) is a major active Juanjuan Xu1 tetracyclic oxindole alkaloid stem from traditional Chinese medicine uncaria species, which fi Xiangrong Song2 has potential activities bene cial for the treatment of AD. However, the application of Hai Huang 2 rhynchophylline for AD treatment is restricted by the low water solubility, low concentration in brain tissue and low bioavailability. And there is no study of brain-targeting therapy with Yue Feng 3 RIN. In this work, we prepared rhynchophylline loaded methoxy poly (ethylene glycol)–poly Chunmei Fu1 (dl-lactide-co-glycolic acid) (mPEG-PLGA) nanoparticles (NPS-RIN), which coupled with 1Key Laboratory of Drug-Targeting and Tween 80 (T80) further for brain targeting delivery (T80-NPS-RIN). Drug Delivery System of the Education Methods: Preparation and characterization of T80-NPS-RIN were followed by the detection Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced of transportation across the blood–brain barrier (BBB) model in vitro, biodistribution and Drug and Sichuan Research Center for neuroprotective effects of nanoparticles. Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan Results: The results indicated T80-NPS-RIN could usefully assist RIN to pass through the University, Chengdu 610041, People’s BBB to the brain. -
European Chemistry Congress June 16-18, 2016 Rome, Italy
conferenceseries.com conferenceseries.com 513th Conference European Chemistry Congress June 16-18, 2016 Rome, Italy Posters Page 98 Adriana A Lopes et al., Chem Sci J 2016, 7:2(Suppl) http://dx.doi.org/10.4172/2150-3494.C1.003 conferenceseries.com European Chemistry Congress June 16-18, 2016 Rome, Italy Unnatural fluoro-oxindole alkaloids produced by Uncaria guianensis plantlets Adriana A Lopes, Bruno Musquiari, Suzelei de C França and Ana Maria S Pereira Universidade de Ribeirão Preto, Brazil atural products and their analogues have been sources of numerous important therapeutic agents. The medicinal plant NU. guianensis (Rubiaceae) cultured in vitro produce four oxindole alkaloids that displays anti-tumoral activity. Natural products can be modified by several approaches, one of which is precursor-directed biosynthesis (PDB). Thus, the aim of this work was apply precursor-directed biosynthesis approach to obtain oxindole alkaloids analogues using in vitro Uncaria guianensis. Plantletes were cultivated into culture medium supplemented with 1mM of 6-fluoro-tryptamine, the indol precursor of alkaloids biosynthesis. U. guianensis explants were maintained at 25±2°C, 55-60% relative humidity under the same photoperiod and light intensity. After 30 days, a methanolic extract from U. guianensis was obtained and analysed by HPLC- DAD analytical procedure. The chromatogram showed four natural alkaloids (mitraphylline, isomitraphylline, rhynchophylline and isorhynchophylline and four additional peaks. Semi-preparative HPLC allowed isolation and purification of these four oxindole alkaloids analogues and the identity of the peaks was confirmed from high-resolution MS data (HRESIMS/MS in positive mode). All data confirmed that Uncaria guianensis produced fluoro-oxindole alkaloids analogues. -
Research Article Antidepressant-Like Activity of the Ethanolic Extract from Uncaria Lanosa Wallich Var. Appendiculata Ridsd in T
Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2012, Article ID 497302, 12 pages doi:10.1155/2012/497302 Research Article Antidepressant-Like Activity of the Ethanolic Extract from Uncaria lanosa Wallich var. appendiculata Ridsd in the Forced Swimming Test and in the Tail Suspension Test in Mice Lieh-Ching Hsu,1 Yu-Jen Ko,1 Hao-Yuan Cheng,2 Ching-Wen Chang,1 Yu-Chin Lin,3 Ying-Hui Cheng,1 Ming-Tsuen Hsieh,1 and Wen Huang Peng1 1 School of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Pharmacy, China Medical University, No. 91 Hsueh-Shih Road, Taichung 404, Taiwan 2 Department of Nursing, Chung Jen College of Nursing, Health Sciences and Management, No. 1-10 Da-Hu, Hu-Bei Village, Da-Lin Township, Chia-Yi 62241, Taiwan 3 Department of Biotechnology, TransWorld University, No. 1221, Jen-Nang Road, Chia-Tong Li, Douliou, Yunlin 64063, Taiwan Correspondence should be addressed to Hao-Yuan Cheng, [email protected] and Wen Huang Peng, [email protected] Received 23 November 2011; Revised 30 January 2012; Accepted 30 January 2012 Academic Editor: Vincenzo De Feo Copyright © 2012 Lieh-Ching Hsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This study investigated the antidepressant activity of ethanolic extract of U. lanosa Wallich var. appendiculata Ridsd (ULEtOH)for two-weeks administrations by using FST and TST on mice. In order to understand the probable mechanism of antidepressant-like activity of ULEtOH in FST and TST, the researchers measured the levels of monoamines and monoamine oxidase activities in mice brain, and combined the antidepressant drugs (fluoxetine, imipramine, maprotiline, clorgyline, bupropion and ketanserin). -
Ep 1553091 A1
Europäisches Patentamt *EP001553091A1* (19) European Patent Office Office européen des brevets (11) EP 1 553 091 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C07D 263/32, C07D 417/14, 13.07.2005 Bulletin 2005/28 C07D 333/20, C07D 413/12, C07D 417/06 (21) Application number: 04726765.3 (86) International application number: (22) Date of filing: 09.04.2004 PCT/JP2004/005119 (87) International publication number: WO 2004/089918 (21.10.2004 Gazette 2004/43) (84) Designated Contracting States: • SAKAMOTO, Johei AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Takatsuki-shi, Osaka 569-1125 (JP) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • NAKANISHI, Hiroyuki Designated Extension States: Takatsuki-shi, Osaka 569-1125 (JP) AL HR LT LV MK • NAKAGAWA, Yuichi Takatsuki-shi, Osaka 569-1125 (JP) (30) Priority: 09.04.2003 JP 2003105267 • OHTA, Takeshi 03.06.2003 JP 2003157590 Takatsuki-shi, Osaka 569-1125 (JP) • SAKATA, Shohei (71) Applicant: Japan Tobacco Inc. Takatsuki-shi, Osaka 569-1125 (JP) Tokyo 105-8422 (JP) • MORINAGA, Hisayo Takatsuki-shi, Osaka 569-1125 (JP) (72) Inventors: • IKEMOTO, Tomoyuki (74) Representative: Takatsuki-shi, Osaka 569-1125 (JP) von Kreisler, Alek, Dipl.-Chem. et al • TANAKA, Masahiro Deichmannhaus am Dom, Takatsuki-shi, Osaka 569-1125 (JP) Postfach 10 22 41 • YUNO, Takeo 50462 Köln (DE) Takatsuki-shi, Osaka 569-1125 (JP) (54) HETEROAROMATIC PENTACYCLIC COMPOUND AND MEDICINAL USE THEREOF (57) A 5-membered heteroaromatic ring compound represented by the formula [I] 1 2 4 5 7 wherein V is CH or N; W is S or O; R and R are each H etc.; X is -N(R )-, -O-, -S-, -SO2-N(R )-, -CO-N(R )- etc.; L is EP 1 553 091 A1 Printed by Jouve, 75001 PARIS (FR) (Cont. -
Full-Text (PDF)
Review ARticle دوره هفتم، شماره سوم، تابستان 1398 دوره هفتم، شماره سوم، تابستان 1398 Review on the Third International Neuroinflammation Congress and Student Fes tival of Neuroscience in Mashhad University of Medical Sciences 1 2 1, 3* Sayed Mos tafa Modarres Mousavi , Sajad Sahab Negah , Ali Gorji 1Shefa Neuroscience Research Center, Khatam Alanbia Hospital, Tehran, Iran 2Department of Neuroscience, Mashhad University of Medical Sciences, Mashhad, Iran 3 Epilepsy Research Center, Department of Neurology and Neurosurgery, Wes tfälische Wilhelms-Universität Müns ter, Müns ter, Germany Article Info: Received: 11 June 2019 Revised: 12 June 2019 Accepted: 13 June 2019 ABSTRACT Introduction: Neuroinflammation congress was the third in a series of annual events aimed to facilitate the inves tigative and analytical discussions on a range of neuroinflammatory diseases. The neuroinflammation congress focused on various neuroinflammatory disorders, including multiple sclerosis, brain tumors, epilepsy, and neurodegenerative diseases. The conference was held in June 11-13, 2019 and organized by Mashhad University of Medical Sciences and Muns ter University, which aimed to shed light on the causes of neuroinflammatory diseases and uncover new treatment pathways. Conclusion: Through a comprehensive scientific program with a broad basic and clinical aspects, we discussed the basic aspects of neuroinflammation and neurodegeneration up to the s tate-of-the-art treatments. In this congress, 334 scientific topics were presented and discussed. Key words: -
7Th World Congress on ADHD: from Child to Adult Disorder
ADHD Atten Def Hyp Disord (2019) 11(Suppl 1):S1–S89 https://doi.org/10.1007/s12402-019-00295-7 ABSTRACTS Ó Springer-Verlag GmbH Austria, part of Springer Nature 2019 7th World Congress on ADHD: From Child to Adult Disorder 25th–28th April, Lisbon Portugal Editors: Manfred Gerlach, Wu¨rzburg Peter Riederer, Wu¨rzburg Andreas Warnke, Wu¨rzburg Luis Rohde, Porto Alegre 123 S2 ABSTRACTS Introduction Dear Colleagues and Friends, We are pleased to have received more than 180 poster abstracts as well as more than 100 poster abstracts from young scientists and clinicians (\ 35 years) who applied for our Young Scientists’ Award. Of all abstracts submitted by our young colleagues, the Scientific Programme Committee has selected the best eight. The authors have been invited to give a presentation as part of our two Young Scientist Award Sessions and to receive a prize money in the amount of 500 Euros. With this approach, we intend to highlight the importance of original scientific contributions, especially from our young colleagues. In this volume, the abstracts of our two Young Scientist Award Sessions come first, followed by regular poster abstracts. These have been organized by topics: Aetiology, Autism Spectrum Disorders, Co-morbidity, Diagnosis, Electrophysiology, Epidemiology, Experimental Models, Genetics, Neuroimaging, Non-pharmacological Treatment, Pathophysiology, Pharmacological Treatment, Quality of Life/Caregiver Burden, Substance Use Disorders and Miscellaneous. Submitted abstracts have not been modified in any way. Please, do not just read the selected poster abstracts, we also encourage you to actively discuss and share your ideas with our young colleagues. Finally, we would like thank all our speakers, contributors and sponsors of our 7th World Congress on ADHD: from Childhood to Adult Disease, and welcome you to join—what we are sure will be—a very enjoyable and highly informative event. -
Ep 2540295 A1
(19) TZZ Z _T (11) EP 2 540 295 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.01.2013 Bulletin 2013/01 A61K 31/404 (2006.01) A61P 25/00 (2006.01) A61P 25/28 (2006.01) (21) Application number: 11171532.2 (22) Date of filing: 27.06.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Briault, Sylvain GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 45000 ORLEANS (FR) PL PT RO RS SE SI SK SM TR • Perche, Olivier Designated Extension States: 45380 LA CHAPELLE SAINT MESMIN (FR) BA ME (74) Representative: Thomas, Dean et al (71) Applicants: Cabinet Ores • Centre national de la recherche scientifique 36 rue de St Pétersbourg 75016 Paris (FR) 75008 Paris (FR) • Centre Hospitalier Régional d’Orléans 45032 Orléans Cédex 1 (FR) (54) Compositions for the treatment of Fragile X syndrome (57) The present invention relates to a composition a fluoro-oxindole or a chloro- oxindole for use in the treat- comprising a maxi-K potassium channel opener the use ment of fragile X syndrome. in the treatment of fragile X syndrome. More specifically the present invention relates to a composition comprising EP 2 540 295 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 540 295 A1 2 Description ularly shyness, limited eye contact, memory problems and difficulty with facial encoding and recognition. Many [0001] The present invention relates to compositions individuals with FXS also meet the diagnostic criteria for for the alleviation of neuropsychiatric symptoms and in autism. -
World of Cognitive Enhancers
ORIGINAL RESEARCH published: 11 September 2020 doi: 10.3389/fpsyt.2020.546796 The Psychonauts’ World of Cognitive Enhancers Flavia Napoletano 1,2, Fabrizio Schifano 2*, John Martin Corkery 2, Amira Guirguis 2,3, Davide Arillotta 2,4, Caroline Zangani 2,5 and Alessandro Vento 6,7,8 1 Department of Mental Health, Homerton University Hospital, East London Foundation Trust, London, United Kingdom, 2 Psychopharmacology, Drug Misuse, and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 3 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 4 Psychiatry Unit, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, 5 Department of Health Sciences, University of Milan, Milan, Italy, 6 Department of Mental Health, Addictions’ Observatory (ODDPSS), Rome, Italy, 7 Department of Mental Health, Guglielmo Marconi” University, Rome, Italy, 8 Department of Mental Health, ASL Roma 2, Rome, Italy Background: There is growing availability of novel psychoactive substances (NPS), including cognitive enhancers (CEs) which can be used in the treatment of certain mental health disorders. While treating cognitive deficit symptoms in neuropsychiatric or neurodegenerative disorders using CEs might have significant benefits for patients, the increasing recreational use of these substances by healthy individuals raises many clinical, medico-legal, and ethical issues. Moreover, it has become very challenging for clinicians to Edited by: keep up-to-date with CEs currently available as comprehensive official lists do not exist. Simona Pichini, Methods: Using a web crawler (NPSfinder®), the present study aimed at assessing National Institute of Health (ISS), Italy Reviewed by: psychonaut fora/platforms to better understand the online situation regarding CEs. -
(ESI) for Integrative Biology. This Journal Is © the Royal Society of Chemistry 2017
Electronic Supplementary Material (ESI) for Integrative Biology. This journal is © The Royal Society of Chemistry 2017 Table 1 Enriched GO terms with p-value ≤ 0.05 corresponding to the over-expressed genes upon perturbation with the lung-toxic compounds. Terms with corrected p-value less than 0.001 are shown in bold. GO:0043067 regulation of programmed GO:0010941 regulation of cell death cell death GO:0042981 regulation of apoptosis GO:0010033 response to organic sub- stance GO:0043068 positive regulation of pro- GO:0010942 positive regulation of cell grammed cell death death GO:0006357 regulation of transcription GO:0043065 positive regulation of apop- from RNA polymerase II promoter tosis GO:0010035 response to inorganic sub- GO:0043066 negative regulation of stance apoptosis GO:0043069 negative regulation of pro- GO:0060548 negative regulation of cell death grammed cell death GO:0016044 membrane organization GO:0042592 homeostatic process GO:0010629 negative regulation of gene ex- GO:0001568 blood vessel development pression GO:0051172 negative regulation of nitrogen GO:0006468 protein amino acid phosphoryla- compound metabolic process tion GO:0070482 response to oxygen levels GO:0045892 negative regulation of transcrip- tion, DNA-dependent GO:0001944 vasculature development GO:0046907 intracellular transport GO:0008202 steroid metabolic process GO:0045934 negative regulation of nucle- obase, nucleoside, nucleotide and nucleic acid metabolic process GO:0006917 induction of apoptosis GO:0016481 negative regulation of transcrip- tion GO:0016125 sterol metabolic process GO:0012502 induction of programmed cell death GO:0001666 response to hypoxia GO:0051253 negative regulation of RNA metabolic process GO:0008203 cholesterol metabolic process GO:0010551 regulation of specific transcrip- tion from RNA polymerase II promoter 1 Table 2 Enriched GO terms with p-value ≤ 0.05 corresponding to the under-expressed genes upon perturbation with the lung-toxic compounds. -
Molecular Pharmacology of K Potassium Channels
Cellular Physiology Cell Physiol Biochem 2021;55(S3):87-107 DOI: 10.33594/00000033910.33594/000000339 © 2021 The Author(s).© 2021 Published The Author(s) by and Biochemistry Published online: online: 6 6March March 2021 2021 Cell Physiol BiochemPublished Press GmbH&Co. by Cell Physiol KG Biochem 87 Press GmbH&Co. KG, Duesseldorf Decher et al.: Molecular Pharmacology of K Channels Accepted: 12 January 2021 2P www.cellphysiolbiochem.com This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna- tional License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Review Molecular Pharmacology of K2P Potassium Channels Niels Dechera Susanne Rinnéa Mauricio Bedoyab,c Wendy Gonzalezb,c Aytug K. Kipera aVegetative Physiology, Institute for Physiology and Pathophysiology, Philipps-University Marburg, Marburg, Germany, bCentro de Bioinformática y Simulación Molecular, Universidad de Talca, Talca, Chile, cMillennium Nucleus of Ion Channels-Associated Diseases (MiNICAD), Universidad de Talca, Talca, Chile Key Words Drug binding sites • K2P potassium channels • Ion channels • Molecular pharmacology Abstract Potassium channels of the tandem of two-pore-domain (K2P) family were among the last potassium channels cloned. However, recent progress in understanding their physiological relevance and molecular pharmacology revealed their therapeutic potential and thus these channels evolved as major drug targets against a large variety of diseases. However, after the initial cloning of the fifteen family members there was a lack of potent and/or selective modulators. By now a large variety of K2P channel modulators (activators and blockers) have been described, especially for TASK-1, TASK-3, TREK-1, TREK2, TRAAK and TRESK channels. -
Research Article Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry
Hindawi BioMed Research International Volume 2018, Article ID 6562309, 8 pages https://doi.org/10.1155/2018/6562309 Research Article Pharmacokinetic Interaction Study of Ketamine and Rhynchophylline in Rat Plasma by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry Lianguo Chen,1 Weiwei You,1 Dingwen Chen,1 Yuan Cai,1 Xianqin Wang ,2 Congcong Wen ,3 and Bo Wu 3 1 Te Tird Clinical Institute Afliated to Wenzhou Medical University & Wenzhou People’s Hospital, Wenzhou 325000, China 2Analytical and Testing Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China 3Laboratory Animal Centre, Wenzhou Medical University, Wenzhou, China Correspondence should be addressed to Congcong Wen; [email protected] and Bo Wu; [email protected] Received 7 March 2018; Accepted 11 April 2018; Published 23 May 2018 Academic Editor: Gail B. Mahady Copyright © 2018 Lianguo Chen et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Eighteen Sprague-Dawley rats were randomly divided into three groups: ketamine group, rhynchophylline group, and ketamine combined with rhynchophylline group (n = 6). Te rats of two groups received a single intraperitoneal administration of 30 mg/kg ketamine and 30 mg/kg rhynchophylline, respectively, and the third group received combined intraperitoneal administration of 30 mg/kg ketamine and 30 mg/kg rhynchophylline together. Afer blood sampling at diferent time points and processing, the concentrations of ketamine and rhynchophylline in rat plasma were determined by the established ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method.